202
Participants
Start Date
May 17, 2017
Primary Completion Date
February 21, 2022
Study Completion Date
February 21, 2022
Ravulizumab
All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilograms (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
Eculizumab
All treatments were given as IV infusions. Participants received 900 mg of eculizumab q2w.
Research Site, Liverpool
Research Site, Kogarah
Research Site, Canberra
Research Site, Melbourne
Research Site, Seoul
Research Site, Woolloongabba
Research Site, Seoul
Research Site, Barcelona
Research Site, Torino
Research Site, The Bronx
Research Site, Marseille
Research Site, Bucheon-si
Research Site, Suwon
Research Site, Milan
Research Site, Baltimore
Research Site, Incheon
Research Site, Madrid
Research Site, Majadahonda
Research Site, Daejeon
Research Site, Vicenza
Research Site, La Tronche
Research Site, Saint-Priest-en-Jarez
Research Site, Daegu
Research Site, Essen
Research Site, Detroit
Research Site, Florence
Research Site, Aachen
Research Site, Strasbourg
Research Site, Pierre-Bénite
Research Site, Paris
Research Site, Amiens
Research Site, Napoli
Research Site, Ulm
Research Site, Los Angeles
Research Site, Duarte
Research Site, Toronto
Research Site, Toronto
Research Site, Montreal
Research Site, Nice
Research Site, Fukushima
Research Site, Kanazawa
Research Site, Shinagawa-ku
Research Site, Suita-shi
Research Site, Suwa-shi
Research Site, Maastricht
Research Site, Nijmegen
Research Site, Seoul
Research Site, Seoul
Research Site, Airdrie
Research Site, Leeds
Research Site, London
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY